Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1 Gastrointestinal 1

Conditions

Cholangiocarcinoma 10 Acrocephalosyndactylia 6 Carcinoma, Transitional Cell 5 Neoplasm Metastasis 4 Breast Neoplasms 4 Gastrointestinal Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Stomach Neoplasms 2 Solid Tumor 2 Recurrence 2 Pancreatic Neoplasms 2 Neoplasms 2 Myeloproliferative Disorders 2 Lung Neoplasms 2 Endometrial Neoplasms 2 Colorectal Neoplasms 2 Carcinoma 2 Urinary Bladder Neoplasms 1 Solid Tumor, Miscellaneous 1 Sarcoma 1 Oligodendroglioma 1 Non-Muscle Invasive Bladder Neoplasms 1 Neoplasms, Unknown Primary 1 Multiple Myeloma 1 Lymphoma, Mantle-Cell 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma, B-Cell 1 Locally Advanced Unresectable Gastric Cancer 1 Liposarcoma 1 Leukemia, Myeloid, Acute 1

Interventions

Imatinib Mesylate 71 Sunitinib 31 regorafenib 17 nilotinib 15 ripretinib 13 avapritinib 7 Laparoscopy 5 Ipilimumab 5 Dasatinib 5 spartalizumab 4 CTLA-4 Antigen 4 Blood Specimen Collection 4 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 4 pexidartinib 3 pazopanib 3 binimetinib 3 Temozolomide 3 Surveys and Questionnaires 3 Surgical Procedures, Operative 3 Paclitaxel 3 Oxaliplatin 3 Observation 3 Nivolumab 3 Midazolam 3 Leucovorin 3 Gemcitabine 3 Biopsy 3 Bevacizumab 3 trametinib 2 tanespimycin 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Gastrointestinal Stromal Tumors × pemigatinib × Clear all

NCT07434843 2026-05-22

PEMIGIST

Dana-Farber Cancer Institute

Phase 2 Recruiting

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡